PDCD1 and non-small cell lung carcinoma: For instance, a retrospective study of 75 patients with unresectable stage III NSCLC reported that induction PD-1/PD-L1 inhibitors combined with chemotherapy, followed by definitive CRT, was associated with acceptable toxicity and a numerically higher two-year overall survival (OS) rate among patients who also received consolidation PD-1/PD-L1 inhibitors.110